A Case Report on Modafinil Dependence

Total Page:16

File Type:pdf, Size:1020Kb

A Case Report on Modafinil Dependence Galore International Journal of Health Sciences and Research Vol.4; Issue: 3; July-September 2019 Website: www.gijhsr.com Case Report P-ISSN: 2456-9321 A Case Report on Modafinil Dependence Dr. Priyanka D’Souza1, Dr. Joylin Jovita Mascarenhas2 1Post Graduate Resident, 2Assistant Professor, Dept. of Psychiatry, Father Muller Medical College, Mangalore Corresponding Author: Dr. Joylin Jovita Mascarenhas ABSTRACT Modafinil, adrafinil, and ampakine are categorized. Eugeroics are devoid of Modafinil is a non-amphetamine stimulant common side effects of traditional frequently prescribed for the treatment of sleep psychostimulants such as excess locomotor disorders such as narcolepsy, obstructive sleep activities, anxiety, jitteriness or interference apnea syndrome, and shift work sleep disorder. in recovery sleep. (9) Due to its Besides, literature also states that Modafinil enhances cognitive functions. Thus, its use dopaminergic activity and low abuse among healthy individuals is increasing to potential, Modafinil has also been used in enhance their alertness or to reduce fatigue. treatment of cocaine, methamphetamine Similar effects of Modafinil have also been abuse and impaired cognitive functions in described in patients with psychiatric illness for alcohol dependent individuals. (10-13) treatment of cognitive dysfunction. Clinical However, the recent reports reported the research has shown that Modafinil improves possibility of dependence in Modafinil due symptoms in patients with major depression, to its sensitivity to dopamine signalling in schizophrenia, and attention-deficit the brain. hyperactivity disorder (ADHD). In early studies, it was stated that Modafinil is a well-tolerated CASE DESCRIPTION drug with low addiction potential. This case report is one of the few case reports on A 55 year old male, presented to Modafinil dependence Psychiatry Inpatient-department with complaints of irritability, suspiciousness and Keywords: Dependence, Modafinil, Non assaultive behavior increased since 2 years. amphetamine, Stimulant On detailed evaluation, it was found that he had history of psychiatric illness since 30 INTRODUCTION years. The course of illness was gradual in Modafinil is a non-amphetamine onset and continuous characterized by stimulant used in narcolepsy, obstructive auditory hallucinations, referential, sleep apnea and also circadian rhythm infidelity and persecutory delusions leading disorder in shift workers. (1) It has also been to the progressive decline in social and tried for disease related fatigue, attention occupational functioning. He was evaluated deficit hyperactivity disorder, Alzheimer’s for the same and initially started on disease, depression and cognitive psychotropics. But patient was poorly impairment in schizophrenia. (2-6) Modafinil compliant to medications. Since 7 years, he has been commercialized as a wake also complained of lethargy and decreased promoting drug in 2003. (7) Even though the interest to work for which he was prescribed mechanism of action is not clear, its Modafinil 150 mg, along with the pharmacological profile is notably different antipsychotics by a private practitioner. He from the traditional psychostimulants, such reported improvement in symptoms. Hence, as amphetamine, cocaine or the treating psychiatrist advised to gradually methylphenidate. (8) A novel class of taper & stop Modafinil. But, patient psychostimulants is eugeroics under which continued to use Modafinil & when denied Galore International Journal of Health Sciences and Research (www.gijhsr.com) 6 Vol.4; Issue: 3; July-September 2019 Priyanka D’Souza et.al. A Case Report on Modafinil Dependence by the doctor (as it was indispensable), dopaminergic and noradrenergic (activation patient would obtain it over the counter of alpha-1 receptors) neurotransmission. Its (OTC). He claimed to have symptoms of wakefulness and memory enhancing worsening of lethargy, multiple aches, properties are mostly due these effects anxiety and disturbances in sleep pattern on Modafinil dependence can be attributed to skipping the Modafinil dose. Since 3 years, its dopamine uptake blockade thereby patient had increased his Modafinil use upto increasing its concentration in dopaminergic 300mg/day on his own after few hours of areas of brain. (14) Modafinil promotes recurrence of symptoms. Patient would cognitive functions such as attention, spend most of his time contemplating about learning and memory. Studies have been procuring the drug rather than spending done on patients with mental disorders. One quality time with family/friends or even of the studies with schizophrenic patients going for a job. with Modafinil administration, in addition to Past history of trihexyphenidyl abuse antipsychotic treatment had promising was noted. Patient also had bronchial results suggestive of cognitive function asthma since childhood, with on and off improvement. (15) In this case, patient who medications for the same. Family history of had history of mental illness had symptoms psychosis in mother and younger sibling of increased sleep in the morning and was present. Physical examination was apathy. Modafinil was used to overcome within normal limits. ECG showed sinus these symptoms. rhythm. His investigations including There are few case reports in the literature haemogram, liver, renal& thyroid function stating that Modafinil dependence can occur test, lipid & glucose profile & neuroimaging in patients with substance abusers, ADHD were all within normal limits. and patients with organic mental disease in He was diagnosed to have Paranoid order to enhance cognitive functions. This is Schizophrenia-continuous (F20.00). Also, also supported with the fact that two of the additional diagnosis of Modafinil previously reported cases had concurrent dependence syndrome was made in view of history of alcohol and benzodiazepine evidence of craving, loss of control & dependence, and the third reported case had unsuccessful efforts to cut down, schizoaffective disorder and the other withdrawal symptoms ,tolerance & ADHD. (16-19) Similarly, in this case patient progressive neglect of alternative had history of Trihexyphenidyl abuse. pleasurables or interest &increased amount There is also a case of Modafinil of time spent on obtaining the substance(as associated psychosis and reports of per dependence criteria of ICD 10) withdrawal phenomenon. (20) Overdose of The dose of modafinil was tapered Modafinil is prone to cause insomnia, gradually. He initially reported of sleep agitation, tachycardia and rise in blood disturbance, irritability, anxiety and pressure. (1) lethargy. We started him on clonazepam for There are no controlled trials or symptomatic management & his symptoms reports available for the treatment of improved gradually. Following this, Modafinil addiction. Treatment with clonazepam was also tapered &stopped. antidepressants like Bupropion, Duloxetine Patient maintained well thereafter only on and treatment with benzodiazepines like anti-pyschotics. Clonazepam has been attempted in previously reported cases. (16-18) In this case, CASE DISCUSSION patient reported of sleep disturbances and Modafinil consists of R-enantiomer anxiety which was managed with and S-enantiomer and the waking effect of benzodiazepines. R-enantiomer has a longer duration. Modafinil is known to act via its effects on Galore International Journal of Health Sciences and Research (www.gijhsr.com) 7 Vol.4; Issue: 3; July-September 2019 Priyanka D’Souza et.al. A Case Report on Modafinil Dependence CONCLUSION Psychopharmacol [Internet]. 2000 Jan Studies have claimed that the abuse 1;14(1):53–60. potential of Modafinil is less & 9. Ferraro L, Antonelli T, O’Connor WT, psychoneuroimmunological approach is Tanganelli S, Rambert FA, Fuxe K. necessary to monitor its potential for abuse. Modafinil: An antinarcoleptic drug with a different neurochemical profile to d- But, this case report shows that modafinil amphetamine and dopamine uptake abuse is not uncommon & clinicians have to blockers. Biol Psychiatry. 1997 Dec bear in their mind about its abuse potential 15;42(12):1181–3. while prescribing it. In the recent years, 10. Dackis CA, Kampman KM, Lynch KG, there is an increase in modafinil use by Pettinati HM, O’Brien CP. A Double-Blind, night shift workers, high school students, Placebo-Controlled Trial of Modafinil for athletes and career oriented people to Cocaine Dependence. Neuropsycho- increase work efficiency without sleep in pharmacology. 2005; 30(1):205–11. the present competitive environment. This 11. Kampman KM, Lynch KG, Pettinati HM, could be because of its easy accessibility Spratt K, Wierzbicki MR, Dackis C, et al. A over the counter. Hence, strict regulations in double blind, placebo controlled trial of modafinil for the treatment of cocaine dispensing these medications must be dependence without co-morbid alcohol ensured. dependence. Drug Alcohol Depend. 2015 Oct 1;155:105–10. REFERENCES 12. Kalechstein AD, De La Garza 2nd R, 1. Lackey G, Alsop J, Albertson T. A 24 Newton TF. Modafinil administration month retrospective study of adult modafinil improves working memory in ingestions. Clin Toxicol. 2007;45:641. methamphetamine-dependent individuals 2. Morein-Zamir S, Turner DC, Sahakian BJ. who demonstrate baseline impairment. Am J A review of the effects of modafinil on Addict. 2010;19(4):340–4. cognition in schizophrenia. Schizophr Bull. 13. Schmaal L, Goudriaan AE, Joos L, Krüse 2007/07/18. 2007 Nov;33(6):1298–306. AM, Dom G, van den Brink W, et al. 3.
Recommended publications
  • Lifestyle Drugs” for Men and Women
    Development of “Lifestyle Drugs” for Men and Women Armin Schultz CRS - Clinical Research Services Mannheim GmbH AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Smart drugs, Quality-of-life drugs, Vanity drugs etc. Lifestyle? Lifestyle-Drugs? Active development? Discovery by chance? AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle A lifestyle is a characteristic bundle of behaviors that makes sense to both others and oneself in a given time and place, including social relations, consumption, entertainment, and dress. The behaviors and practices within lifestyles are a mixture of habits, conventional ways of doing things, and reasoned actions „Ein Lebensstil ist [...] der regelmäßig wiederkehrende Gesamtzusammenhang der Verhaltensweisen, Interaktionen, Meinungen, Wissensbestände und bewertenden Einstellungen eines Menschen“ (Hradil 2005: 46) Different definitions in social sciences, philosophy, psychology or medicine AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle Many “subdivisions” LOHAS: “Lifestyles of Health and Sustainability“ LOVOS: “Lifestyles of Voluntary Simplicity“ SLOHAS: “Slow Lifestyles of Happiness and Sustainability” PARKOS: “Partizipative Konsumenten“ ……. ……. ……. AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Lifestyle drug is an imprecise term commonly applied to medications which treat non-life threatening and non-painful conditions such as baldness, impotence, wrinkles, or acne, without any medical relevance at all or only minor medical relevance relative to others. Desire for increase of personal well-being and quality of life It is sometimes intended as a pejorative, bearing the implication that the scarce medical research resources allocated to develop such drugs were spent frivolously when they could have been better spent researching cures for more serious medical conditions.
    [Show full text]
  • Modafinil and Modafinil Analogues: Free Radical Mechanism of the Eugeroic and Cognitive Enhancment Effect Clifford Fong
    Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford Fong To cite this version: Clifford Fong. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect. [Research Report] Eigenenergy. 2018. hal-01933737 HAL Id: hal-01933737 https://hal.archives-ouvertes.fr/hal-01933737 Submitted on 24 Nov 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford W. Fong Eigenenergy, Adelaide, South Australia. Keywords: Modafinil, modafinil-like analogues, eugeroic effect, cognitive enhancement, free radicals, quantum mechanics Abbreviations Dopamine DA, dopamine transporter DAT, Dissociative electron transfer or attachment DET, Linear free energy relationship LFER, free energy of water desolvation ΔG desolv,CDS , lipophilicity free energy ΔG lipo,CDS, cavity dispersion solvent structure of the first solvation shell CDS, highest occupied molecular orbital HOMO, lowest unoccupied molecular orbital LUMO, multiple correlation coefficient R 2, the F test of significance, standards errors for the estimate (SEE) and standard errors of the variables SE(ΔG desolCDS ), SE(ΔG lipoCDS ), SE(Dipole Moment), SE (Molecular Volume), transition state TS, reactive oxygen species ROS.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]
  • A New Orientation to the Therapeutics of Psychiatric Disorders
    Article NIMHANS Journal A New Orientation to the Therapeutics of Psychiatric Disorders Volume: 14 Issue: 04 October 1996 Page: 249-261 N Pradhan, - Department of Psychopharmacology, National Institute of Mental Health & Neuro Sciences, Bangalore 560 029, India Abstract In the context of advances in our knowledge of cellular and molecular neurobiology, the therapeutics of psychiatric disorders demands a new orientation. It is surprising that despite considerable advances in neurobiology, our comprehension of neural basis of behaviour, and hence abnormal states of mind encountered in clinical psychiatry practice, remains rudimentary. The current pharmacological management of psychiatric disorders are vastly empirical in nature. The neurobiological strategy to understand behavioural problems or deducing the etiology of psychiatric illnesses from the specificity of drug action is as misleading as deducing the etiology of enteric fever from the action of antipyretic drugs. The current successes of broad spectrum drugs in the management of intractable disorders like schizophrenia, has freshened the debate on the role of multiple-interacting neurochemical systems underlying the behavioural dysfunctions. Against this background, this review paper aims to generate a new perspective for psychopharmacology research. The prototype psychiatric disorders and pharmacological agents used in their treatment are discussed. Some of the newer drugs in experimental stages are also included in this topic. This new orientation marks the end of one generation of view that advocated neurochemical specificity of drug action in the treatment of psychiatric illness. This may also herald the beginning of the emergence of a comprehensive, global and holistic view of brain, behaviour and mental illness from the pharmacological view point.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • NFLIS-Drug Selected Substance List
    2017-2020 NFLIS-Drug Substance List (Sorted by Date) Date Added NFLIS Substance Name Synonyms Chemical Name Structure InChI Formula to NFLIS- Drug InChI=1S/C16H20BrN/ c17-14-1-3-15(4-2-14)18-16-12-6-10-5-11 Bromantane ladasten N-(4-bromophenyl)adamantan-2-amine C16H20BrN 12/7/20 (8-12)9-13(16)7-10/h1-4,10-13,16,18H, 5-9H2 InChI=1S/C21H29FN2O3/ c1-4-27-21(26)19(15(2)3)23-20(25)17-14- ethyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3- 5F-EMB-PICA EMB-2201; 5-fluoro-EMB-PICA 24(13-9-5-8-12-22)18-11-7-6-10-16(17)18 C21H29FN2O3 11/12/20 methylbutanoate /h6-7,10-11,14-15,19H, 4-5,8-9,12-13H2,1-3H3,(H,23,25) InChI=1S/C20H27FN2O3/ c1-20(2,3)17(19(25)26-4)22-18(24)15-13- methyl 2-(1-(4-fluorobutyl)-1H-indole-3- 4F-MDMB-BUTICA 4-fluoro-MDMB-BUTICA; 4F-MDMB-BICA 23(12-8-7-11-21)16-10-6-5-9-14(15)16/ C20H27FN2O3 10/23/20 carboxamido)-3,3-dimethylbutanoate h5-6,9-10,13,17H,7-8,11-12H2,1-4H3,(H, 22,24) InChI=1S/C10H14BrNO2/ 4-methoxy-6-[(1E)-2-phenylethenyl]-5,6-dihydro-2H- 2Br-4,5-Dimethoxyphenethylamine 2-bromo-4,5-dimethoxyphenethylamine c1-13-9-5-7(3-4-12)8(11)6-10(9)14-2/ C10H14BrNO2 10/2/20 pyran-2-one h5-6H,3-4,12H2,1-2H3 InChI=1S/C16H22FNO/ 4-fluoro-3-methyl-alpha-PVP; 4F-3-methyl-alpha- c1-3-6-15(18-9-4-5-10-18)16(19)13-7-8-1 4F-3-Methyl-alpha-PVP 4-fluoro-3-methyl-alpha-pyrrolidinopentiophenone C16H22FNO 10/2/20 pyrrolidinovalerophenone 4(17)12(2)11-13/h7-8,11,15H, 3-6,9-10H2,1-2H3 InChI=1S/C21H26N4O3/ N,N-diethyl-2-[2-(4-methoxybenzyl)-5-nitro-1H- c1-4-23(5-2)12-13-24-20-11-8-17(25(26)2 Metonitazene C21H26N4O3 9/15/20 benzimidazol-1-yl]ethanamine
    [Show full text]
  • World of Cognitive Enhancers
    ORIGINAL RESEARCH published: 11 September 2020 doi: 10.3389/fpsyt.2020.546796 The Psychonauts’ World of Cognitive Enhancers Flavia Napoletano 1,2, Fabrizio Schifano 2*, John Martin Corkery 2, Amira Guirguis 2,3, Davide Arillotta 2,4, Caroline Zangani 2,5 and Alessandro Vento 6,7,8 1 Department of Mental Health, Homerton University Hospital, East London Foundation Trust, London, United Kingdom, 2 Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 3 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 4 Psychiatry Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, 5 Department of Health Sciences, University of Milan, Milan, Italy, 6 Department of Mental Health, Addictions’ Observatory (ODDPSS), Rome, Italy, 7 Department of Mental Health, Guglielmo Marconi” University, Rome, Italy, 8 Department of Mental Health, ASL Roma 2, Rome, Italy Background: There is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders. While treating cognitive deficit symptoms in neuropsychiatric or neurodegenerative disorders using CEs might have significant benefits for patients, the increasing recreational use of these substances by healthy individuals raises many clinical, medico-legal, and ethical issues. Moreover, it has become very challenging for clinicians to Edited by: keep up-to-date with CEs currently available as comprehensive official lists do not exist. Simona Pichini, Methods: Using a web crawler (NPSfinder®), the present study aimed at assessing National Institute of Health (ISS), Italy Reviewed by: psychonaut fora/platforms to better understand the online situation regarding CEs.
    [Show full text]
  • 2019 Prohibited List
    THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2019 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2019 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES NON-APPROVED SUBSTANCES Mestanolone; S0 Mesterolone; Any pharmacological substance which is not Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- addressed by any of the subsequent sections of the 3-one); List and with no current approval by any governmental Metenolone; regulatory health authority for human therapeutic use Methandriol; (e.g. drugs under pre-clinical or clinical development Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- or discontinued, designer drugs, substances approved androstan-3-one); only for veterinary use) is prohibited at all times. Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); ANABOLIC AGENTS Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- S1 androst-1-en-3-one); Anabolic agents are prohibited. Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); 1. ANABOLIC ANDROGENIC STEROIDS (AAS) Methyltestosterone; a. Exogenous*
    [Show full text]
  • Synthesis Of
    S S symmetry Article ArticleSynthesis of (R)-Modafinil via Organocatalyzed and SynthesisNon-Heme of Iron (R)-Modafinil-Catalyzed viaSulfoxidation Organocatalyzed Using H and2O2 Non-Hemeas an Environmentally Iron-Catalyzed Benign Sulfoxidation Oxidant Using H2O2 as an Environmentally Benign Oxidant Felix E. Held, Kerstin A. Stingl and Svetlana B. Tsogoeva * FelixDepartment E. Held, of Kerstin Chemistry A. and Stingl Pharmacy, and Svetlana Organic B.Chemistry Tsogoeva Chair * I and Interdisciplinary Center for DepartmentMolecular Materials of Chemistry (ICMM), and University Pharmacy, Organicof Erlangen Chemistry-Nuremberg, Chair Henkestraße I and Interdisciplinary 42, 91054 CenterErlangen, for Germany Molecular; [email protected] (ICMM), (F.E.H.); University kerst [email protected] Erlangen-Nuremberg, (K.A.S.) Henkestraße 42, 91054 Erlangen, Germany; [email protected]* Correspondence (F.E.H.);: svetlana. [email protected]@fau.de; Tel.: (K.A.S.) +49-9131-85-22541 *AcademicCorrespondence: Editor: Stephane [email protected]; Béllemin-Laponnaz Tel.: +49-9131-85-22541 AcademicReceived: 11 Editor: May Stephane2017; Accepted: Béllemin-Laponnaz 7 June 2017; Published: 16 June 2017 Received: 11 May 2017; Accepted: 7 June 2017; Published: 16 June 2017 Abstract: The first organocatalyzed sulfoxidation reaction towards enantioenriched (R)-modafinil Abstract:(ArmodafinilThe® first), a drug organocatalyzed against narcolepsy, sulfoxidation is reported reaction here. towards A series enantioenriched of chiral organocatalysts (R)-modafinil, e.g., (Armodafinildifferent chiral®), BINOL a drug-phosphates, against narcolepsy, or a fructose is reported-derived here. N-substituted A series oxazolidinone of chiral organocatalysts, ketone (Shi e.g.,catalyst) different were chiral applied BINOL-phosphates, for the sulfoxidation or a fructose-derived reaction with environmentallyN-substituted oxazolidinone friendly H2O ketone2 as a (Shiconvenient catalyst) oxygen were appliedtransferring for the agent.
    [Show full text]
  • Myelogram-Medications-To-Avoid.Pdf
    Medication to be held 48 Banaflex /skeletal muscle relaxer Clozaril/antischizophenia HOURS BEFORE AND 24 HOURS Bancap/contains caffei Cogentin/antidyskinectic/ant AFTER MYELOGRAM Banzel/seizure adjunct iemetic/antipsychotic Updated December 2016 BC powder/ contains caffeine Compazine/phenothiazine Belviq/appetite suppressant Concerta/CNS stimulant Abilify / antipsychotic Bevespi contains formoterol Contrave/antidepressant Acetophenazine/ antipsychotic Benzphetamine/appetite Cyclizine/ antiemetic Adderall/amphetamine and suppressant antivertigo agent dextroamphetamine Bismuth subcitrate potassium/ Cyclobenzaprine/muscle Adipex-P/stimulant/ anorectic mineral relaxer Adsuva/antidepressant Bonine/meclicine Cylert/ADHD agent Adphen/ /antidepressant Bontril/appetite suppressant Cymbalta/antidepressant/tri appetite suppressant Bontril PDM/appetite suppressant cyclic Adipost/ appetite suppressants, Bortezomib/antineoplastics Sympathomimetic (Systemic Brintxelli / antidepressant Adrafinil/cognitive enhancer Bucladin-S softab/antiemetic Dapex/appetite suppressant Alatrofloxacin/ antibacterial antivertigo Dayquil/contains caffeine Aliskiren Bucet/contains caffeine Darvon 65/contain caffeine Hemifumarate/antihypertensive Buclizine/antiemetic/antivertigo Daytrana/CNS stimulant direct renal inhibitor / Budeption/antidepressant Desipramine/tricyclic/antide Alsuma/s Buphenamine/appetite suppressant pressant Amaphen/ barbituate Buproban/antidepressantr Desoxyn/amphetamine Amitriptyline/ tricyclic BupropionBuffets/caffeine Desvenlafaxine succinate/ antidepressant
    [Show full text]
  • The Neurophysiological, Behavioral and Cognitive Enhancing Effects of Adrafinil in the Aging Canine
    The Neurophysiological, Behavioral and Cognitive Enhancing Effects of Adrafinil in the Aging Canine Heather M. Callahan A thesis submitted in conformity with the requirements for the degree of Masters of Science Graduate Department of Physiology University of Toronto O Copyright by Heather M. Callahan 2001 National Library Bibliothèque nationale du Canada Acquisitions and Acquisitions et Bibliographie Services services bibliographiques 395 WeUingîon Street 395, nie Wellington Ottawa ON KIA ON4 Ottawa ON K1A ON4 Canada Canada The author has granted a non- L'auteur a accordé une licence non exclusive licence allowing the exclusive permettant a la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or seil reproduire, prêter, distribuer ou copies of this thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la forme de rnicrofiche/film, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fiom it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. 1. Abstract The Neurophysiological, Behaviord and Cognitive Enhancing Effects of Adrafiil in the Aging Canine Masters of Science, 200 1 Heather M. Callahan Department of Physiology?University of Toronto. Adratinil is a behavioral stimulant that is currently being used in France to prornote vigilance in the elderly. Most of our undentandinç of adrafinil cornes From it's main metabolite.
    [Show full text]
  • Microsoft Word
    AUTORISES INTERDITS AC. ACETYLSALICYLIQUE AC. MEFENAMIQUE AC. CLAVULANIQUE AC. NALIDIXIQUE AC. FUSIDIQUE AC. PIPEMIDIQUE AC. NIFLUMIQUE AC. PIROMIDIQUE AC. OXOLINIQUE ACITRETINE AC. TIAPROFENIQUE ADRAFINIL AC. TIENILIQUE ALCOOL AC. TRANEXAMIQUE ALIZAPRIDE ACAMPROSATE ALLOPURINOL ACEBUTOLOL ALMINOPROFENE ACETAZOLAMIDE ALPRAZOLAM ACICLOVIR ALVERINE ACTH AMBROXOL ADRENALINE AMIDOPYRINE ALFENTANIL AMINEPTINE ALFUZOSINE AMINOGLUTHETIMIDE ALIMEMAZINE AMIODARONE AMANTADINE AMISULPRIDE AMFEPRAMONE AMOBARBITAL AMIKACINE ANDROGENES AMILORIDE ARTICAINE AMITRIPTYLINE ASTEMIZOLE AMLODIPINE BACLOFENE AMOXAPINE BARBITURIQUES AMOXICILLINE BENFLUOREX AMPHOTERICINE B BENZBROMARONE APTOCAINE BENZYL THIOURACILE ATENOLOL BEPRIDIL ATRACURIUM BETAHISTINE ATROPINE BIPERIDENE AZATHIOPRINE BISOPROLOL BENAZEPRIL BROMOCRIPTINE BENSERAZIDE BUPIVACAINE (*) BETA-ALANINE BUSPIRONE BETAXOLOL CAPTOPRIL BEZAFIBRATE CARBAMAZEPINE BLEOMYCINE CEFACLOR BROMAZEPAM CEFPODOXIME BROMURE CEFUROXIME BUFLOMEDIL CHLORAMPHENICOL BUPRENORPHINE CHLORMEZANONE BUTACAINE CHLOROQUINE (*) BUTYLHYOSCINE CIBENZOLINE CARBIMAZOLE CICLETANINE CARPIPRAMINE CIPROFIBRATE CEFIXIME CLINDAMYCINE CEFOTAXIME CLOBAZAM CEFTAZIDIME CLOFIBRATE CEFTRIAXONE CLOMETHIAZOLE CELIPROLOL CLOMIFENE CERIVASTATINE CLONIDINE CETIRIZINE CLORAZEPATE CHLORAL HYDRATE CLOTIAZEPAM CHLORDIAZEPOXIDE CYCLOPHOSPHAM 1 DE CHLORPROMAZINE CYPROTERONE CICLOSPORINE DANAZOL CILAZAPRIL DAPSONE CIMETIDINE DENORAL® CIPROFLOXACINE DEXFENFLURAMINE CISAPRIDE DEXTROMORAMIDE CITALOPRAM DEXTROPROPOXYPHENE CLARITHROMYCINE DIAZEPAM CLIDINIUM DIHYDRALAZINE
    [Show full text]